SH
Shivalik Rasayan Ltd (SHIVALIK)
₹282.90
Mkt cap
₹489 Cr
P/E ratio
34.20
P/B
0.73
Div yield
0.16%
ROE
2.18%
ROCE
4.76%
EPS (TTM)
₹8.27
Book value
₹387
52W range
206–437
Sector
Commodities
Price history
Previous close
Incorporated in 1979, Shivalik Rasayan Ltd is a manufacturer of Agrochemicals & Active Pharma Ingredients [1]
NSE SHIVALIKBSE 539148
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−35.25% from high₹283
₹206+37.06% from low₹437
Current
₹282.90
Prev close
₹291.65
Day
−3.00%
Price performance
1D
−3.31%
1W
−7.59%
1M
−11.46%
3M
+4.87%
6M
+10.63%
1Y
−34.75%
YTD
−21.79%
Financials
Revenue, profit & margin
P/E ratio
34.2×
SHIVALIK is 89% above the sector median of 18.1×
SHIVALIK34.2×
Sector median18.1×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 67.05 | 70.23 | 71.23 | 74.63 | 82.44 | 85.31 | 69.39 | 89.31 | 93.84 | 82.04 | 102.82 | 96.34 | 100.63 | |
| YoY Sales growth | +19.03% | +22.44% | +13.19% | +15.76% | +22.95% | +21.47% | -2.58% | +19.67% | +13.83% | -3.83% | +48.18% | +7.87% | +7.24% | |
| Expenses | 57.39 | 61.37 | 61.94 | 65.25 | 70.68 | 71.99 | 63.63 | 78.33 | 81.80 | 71.72 | 90.39 | 85.16 | 85.79 | |
| Operating Profit | 9.66 | 8.86 | 9.29 | 9.38 | 11.76 | 13.32 | 5.76 | 10.98 | 12.04 | 10.32 | 12.43 | 11.18 | 14.84 | |
| OPM % | 14.41% | 12.62% | 13.04% | 12.57% | 14.26% | 15.61% | 8.30% | 12.29% | 12.83% | 12.58% | 12.09% | 11.60% | 14.75% | |
| Other Income | 0.56 | 1.50 | 1.49 | 0.64 | 0.35 | 1.60 | 5.71 | 0.60 | 0.39 | 1.18 | 1.92 | 0.97 | 0.01 | |
| Interest | 1.96 | 1.58 | 2.61 | 1.92 | 2.45 | 2.26 | 2.71 | 2.62 | 2.22 | 2.31 | 2.46 | 2.08 | 3.45 | |
| Depreciation | 3.44 | 3.01 | 3.11 | 3.50 | 4.66 | 4.84 | 2.78 | 4.82 | 4.73 | 5.06 | 4.16 | 4.41 | 4.61 | |
| Profit before tax | 4.82 | 5.77 | 5.06 | 4.60 | 5.00 | 7.82 | 5.98 | 4.14 | 5.48 | 4.13 | 7.73 | 5.66 | 6.79 | |
| Tax % | 45.02% | 24.78% | 9.09% | 16.09% | 11.60% | 11.38% | 13.21% | 31.88% | 21.35% | 11.14% | 7.12% | 20.49% | 20.62% | |
| Net Profit | 2.65 | 4.34 | 4.60 | 3.86 | 4.43 | 6.94 | 5.19 | 2.82 | 4.31 | 3.67 | 7.18 | 4.50 | 5.40 | |
| EPS in Rs | 1.21 | 1.97 | 2.21 | 2.26 | 2.58 | 3.39 | 2.62 | 1.02 | 1.94 | 1.71 | 2.88 | 2.16 | 2.30 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202646.54%Promoter
Promoters46.54%0.83
FIIs0.72%0.48
DIIs0.01%0.01
Public52.72%1.29
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| UPL | ₹559.40 | 24.67 | 47,208 | 1.07% | 452 | −12.95% | 11,860 | −1.32% | 10.11% |
| P I Industries | ₹1,714.80 | 32.81 | 26,017 | 0.87% | 122 | −70.14% | 1,702 | −9.11% | 14.99% |
| Sumitomo Chemi. | ₹346.60 | 31.49 | 17,300 | 0.38% | 156 | −12.29% | 891 | −2.57% | 23.48% |
| Bayer Crop Sci. | ₹3,447.00 | 20.78 | 15,492 | 4.35% | 166 | +8.84% | 1,251 | −19.49% | 29.14% |
| Sharda Cropchem | ₹730.50 | 10.24 | 6,591 | 2.05% | 92 | +23.52% | 1,052 | +13.19% | 30.25% |
| Dhanuka Agritech | ₹907.85 | 14.29 | 4,047 | 0.22% | 109 | +16.23% | 658 | +9.91% | 23.76% |
| Rallis India | ₹189.25 | 17.92 | 3,680 | 1.59% | 85 | −23.62% | 858 | −0.35% | 14.14% |
| Shivalik Rasayan | ₹305.15 | 34.16 | 489 | 0.16% | 5 | +20.98% | 101 | +7.24% | 4.76% |
| Median: 25 Co. | ₹238.85 | 18.06 | 1,412 | 0.16% | 25 | −3.25% | 372 | +4.27% | 14.99% |
Filings
Annual reports15
Concall transcripts6
Announcements5
Financial Results For The Quarter And Half Year Ended On 30.09.2026 13 NovBoard Meeting Intimation for Approval Of Un-Audited Financial Results Of The Company (Standalone & Consolidated) For The Quarter And Half Year Ended On September 30, 2026 4 Nov - Board meeting on November 13, 2026 to approve Q2 FY27 standalone and consolidated results.Announcement Under Regulation 30 Of LODR 3 Nov - Shivalik Rasayan filed USFDA DMF for Avapritinib API; complete assessment completed.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 29 SepAnnouncement under Regulation 30 (LODR)-Acquisition 29 Sep - Company received Regulation 29 disclosureGinnerup Capital ApS for warrant acquisition.






